Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System is an experimental contraceptive method developed by Massachusetts General Hospital. It is designed to induce "medical castration" using a gonadotropin-releasing hormone (GnRH) agonist, specifically leuprolide, which suppresses the hypothalamic-pituitary-gonadal axis to inhibit ovulation. To prevent the side effects associated with hormone deficiency (such as bone loss and vasomotor symptoms), the ring simultaneously releases physiologic levels of human sex steroid hormones (estrogen and progestin). This dual-action approach aims to provide effective contraception while maintaining a normal hormonal milieu. The system is currently being evaluated in Phase 1/2 clinical trials for safety, pharmacokinetics, and efficacy in healthy women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ethylvinyl Acetate Vaginal Ring Delivery System.